11-Oxygenated Androgens Useful in the Setting of Discrepant Conventional Biomarkers in 21-Hydroxylase Deficiency
Open accessThe DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
Context: Serum 17-hydroxyprogesterone (17OHP) and androstenedione (A4) are the conventional biomarkers used to assess disease control in patients with 21-hydroxylase deficiency (21OHD). However, discrepancy between the two is not uncommon, limiting interpretation. Objective: To evaluate 11-oxyandrogens in discriminating good versus poor disease control in 21OHD in the setting of discrepant 17OHP and A4. Methods: Retrospective analysis of 2738 laboratory assessments obtained as part of Natural History Study of congenital adrenal hyperplasia (CAH) at the National Institutes Health Clinical Center. Patients with discrepant 17OHP and A4 and available sera were selected. A 15-steroid mass-spectrometry panel was performed in sera from patients with 21OHD and age- and sex-matched controls. Patients were categorized in “good” or “poor” control based on clinical assessment (bone age advancement, signs and symptoms of precocious puberty, menstrual irregularity, hirsutism, or hypogonadotrophic hypogonadism). Results: Discrepant 17OHP and A4 was found in 469 (17%) laboratory assessments. Of these, 403 (86%) had elevated 17OHP with A4 in reference range. Of 46 patients with available sera, 30 (65%) were in good control. Median fold elevation relative to controls was higher in patients with poor versus good control for 11-hydroxytestosterone (median [interquartile range], 2.82 [1.25-5.43] vs 0.91 [0.49- 2.07], P = .003), and 11-ketotestosterone (3.57 [2.11-7.41] vs 1.76 [1.24-4.00], P = .047). Fold elevation of 11-hydroxytestosterone between 3.48 (sensitivity 97%, specificity 47%) and 3.88 (sensitivity 100%, specificity 40%) provided the best discrimination between poor vs good control. Conclusion: 11-Oxyandrogens, especially 11-hydroxytestosterone, may be useful in the management of CAH when conventional biomarkers are inconclusive.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional challenges in the management of 21OHD derive from the uncertainties surrounding the optimal use of biomarkers to assess disease control (10, 11).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [11]
In the citing paper
“11-oxyandrogens were found to correlate with parameters of poor 21OHD control (11, 17).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [11]
In the citing paper
“Although 17OHP and A4 show good correlation, we previously found that 17% of laboratory evaluations done in the early morning resulted in discrepant findings between these two traditional biomarkers (11).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [11]
In the citing paper
“A retrospective analysis of >2,700 laboratory assessments in patients with CAH showed that 17% of samples had discrepant 17-OHP and androstenedione, and that elevated 11-oxygenated androgens could be used to identify those with poor disease control when traditional biomarkers are inconclusive52.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [52]
Citations
Cites
Moving to a World Beyond “ p < 0.05”
Wasserstein, R. L., Schirm, A. L., & Lazar, N. A. (2019) · The American Statistician · doi:10.1080/00031305.2019.1583913 · Cited by 2,976
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234 · cited 2×
“The most common form is 21-hydroxylase deficiency (21OHD), with its classic form accounting for more than 95% of all cases and affecting 1 in 14 000 to 1 in 18 000 newborns [1].”
BackgroundSelf-citationMartin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341 · cited 1×
“Patients with 21OHD need lifetime glucocorticoid and mineralocorticoid replacement at doses adequate to treat adrenal insufficiency and to avoid excess accumulation of androgens, which are produced from accumulation of the precursor products 17OHP and A4 [2].”
BackgroundSelf-citationMartin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339 · cited 1×
“For example, it may take 6 to 12 months after an intervention to see an improvement in hirsutism [36].”
BackgroundClinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313 · cited 1×
“A serum 17OHP level of 1200 ng/dL is often used as the upper limit of acceptable range [7, 8].”
BackgroundSelf-citationPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Turcu, A. F., Nanba, A. T., Chomic, R., Upadhyay, S. K., Giordano, T. J., Shields, J. J., Merke, D. P., Rainey, W. E., & Auchus, R. J. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1181 · Cited by 231 · cited 3×
“Elevated 11-oxyandrogens correlate positively with total adrenal volume and testicular adrenal rest tumors in patients with 21OHD, [25] and these steroids show a median elevation of 3- to 4-fold relative to age- and sex-matched controls in patients with 21OHD [24].”
BackgroundSelf-citationRege, J., Nakamura, Y., Satoh, F., Morimoto, R., Kennedy, M. R., Layman, L. C., Honma, S., Sasano, H., & Rainey, W. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2912 · Cited by 227
Storbeck, K.-H., Bloem, L. M., Africander, D., Schloms, L., Swart, P., & Swart, A. C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.006 · Cited by 198 · cited 2×
“In vitro studies have shown that the maximum androgenic potency of 11KT approaches that of testosterone while 11OHT has modest androgenic potency [27, 30].”
BackgroundRege, J., Turcu, A., Kasa-Vubu, J. Z., Lerario, A. M., Auchus, G. C., Auchus, R. J., Smith, J. M., White, P. C., & Rainey, W. E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00736 · Cited by 154 · cited 2×
“The adrenal origin of 11-oxyandrogens is consistent with several studies, which show similar levels in both sexes with no evidence of decline following menopause [22], rise in levels during normal and premature adrenarche [20], higher concentrations in the adrenal vein than in the periphery, rise in levels after adren…”
BackgroundSelf-citationPretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159867 · Cited by 148
A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids
Pretorius, E., Arlt, W., & Storbeck, K.-H. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.014 · Cited by 142 · cited 1×
“The reason for this is not quite clear; however, 11OHT appears to be directly produced by the adrenal cortex, whereas 11KT is produced in the periphery from excess adrenal metabolites, predominantly from 11OHA4, via 11KA4 [28, 29].”
BackgroundStrott, C. A., Yoshimi, T., & Lipsett, M. B. (1969) · Journal of Clinical Investigation · doi:10.1172/jci106052 · Cited by 132
11-oxygenated C19 steroids Do not decline with age in women
Nanba, A. T., Rege, J., Ren, J., Auchus, R. J., Rainey, W. E., & Turcu, A. F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02527 · Cited by 113 · cited 2×
“Quantitation of 15 steroids in peripheral sera was performed by liquid chromatography/tandem mass spectrometry (LC-MS/MS) as previously described [22].”
BackgroundMethodSelf-citationTurcu, A. F., Mallappa, A., Elman, M. S., Avila, N. A., Marko, J., Rao, H., Tsodikov, A., Auchus, R. J., & Merke, D. P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3989 · Cited by 107 · cited 2×
“Elevated 11-oxyandrogens correlate positively with total adrenal volume and testicular adrenal rest tumors in patients with 21OHD, [25] and these steroids show a median elevation of 3- to 4-fold relative to age- and sex-matched controls in patients with 21OHD [24].”
BackgroundSelf-citationLippe, B. M., LAFRANCHI, S. H., Lavin, N., Parlow, A. F., Coyotupa, J., & Kaplan, S. A. (1974) · The Journal of Pediatrics · doi:10.1016/s0022-3476(74)80340-9 · Cited by 98 · cited 3×
“This may be due to the smaller diurnal variation of A4 than 17OHP [1518] and rapid changes in serum levels of 17OHP after oral or intramuscular stress dose [11, 17, 19].”
BackgroundCongenital adrenal hyperplasia: time to replace 17OHP with 21-deoxycortisol
Miller, W. L. (2019) · Hormone Research in Paediatrics · doi:10.1159/000501396 · Cited by 93 · cited 1×
“Its use has been proposed for newborn screening in lieu of 17OHP to help reduce rate of false positives as 21dF is not elevated in premature newborns [33, 34].”
BackgroundCharmandari, E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.10.4679 · Cited by 84
Fiet, J., Bouc, Y. L., Guechot, J., Hélin, N., Maubert, M.-A., Farabos, D., & Lamazière, A. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1048 · Cited by 80
Development of a Novel Cell Based Androgen Screening Model
Campana, C., Rege, J., Turcu, A. F., Pezzi, V., Gomez-Sanchez, C. E., Robins, D. M., & Rainey, W. E. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.11.005 · Cited by 73 · cited 2×
“This discriminatory potential of 11OHT and 11KT but not 11OHA4 and 11KA4 might be explained by the higher androgenic activity of the former [21, 27].”
BackgroundSelf-citationMonitoring of Therapy in Congenital Adrenal Hyperplasia
Dauber, A., Kellogg, M., & Majzoub, J. A. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.146035 · Cited by 72 · cited 1×
“A serum 17OHP level of 1200 ng/dL is often used as the upper limit of acceptable range [7, 8].”
BackgroundMeasurement of 17-Hydroxyprogesterone in Human Plasma
Strott, C. A., & Lipsett, M. B. (1968) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-28-10-1426 · Cited by 55 · cited 1×
“17OHP also varies with menstrual phase in females and timing of the sample in relation to the last dose of glucocorticoid [10, 11].”
BackgroundPreclinical challenges in steroid analysis of human samples
Ceglarek, U., Werner, M., Kortz, L., Körner, A., Kieß, W., Thiery, J., & Kratzsch, J. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.03.039 · Cited by 53 · cited 1×
“Moreover, when the hypothalamic–pituitary–adrenal axis is not suppressed, large excursions in serum 17OHP levels may occur promptly in response to stress, for example, venipuncture, which is particularly relevant in children [9].”
BackgroundEl‐Maouche, D., Collier, S., Prasad, M., Reynolds, J. C., & Merke, D. P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12507 · Cited by 53 · cited 1×
“Third, dehydroepiandrosterone sulfate, the predominant adrenal androgen precursor in healthy individuals is suppressed in patients with CAH for reasons that are not quite clear [5, 6].”
BackgroundSelf-citationDebono, M., Mallappa, A., Gounden, V., Nella, A. A., Harrison, R. F., Crutchfield, C. A., Backlund, P. S., Soldin, S. J., Ross, R. J., & Merke, D. P. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0064 · Cited by 53 · cited 2×
“This may be due to the smaller diurnal variation of A4 than 17OHP [1518] and rapid changes in serum levels of 17OHP after oral or intramuscular stress dose [11, 17, 19].”
BackgroundSelf-citationCosta‐Barbosa, F. A., Tonetto‐Fernandes, V. F., Carvalho, V. M., Nakamura, O. H., Moura, V., Bachega, T. A. S. S., Vieira, J. G. H., & Kater, C. E. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03871.x · Cited by 50 · cited 1×
“Superiority of adrenocorticotropin-stimulated 21dF versus 17OHP in the identification of heterozygote carriers has also been demonstrated [35].”
BackgroundBarnard, L., Gent, R., van Rooyen, D., & Swart, A. C. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.034 · Cited by 41
Circadian Variation in Plasma 17-Hydroxyprogesterone in Patients with Congenital Adrenal Hyperplasia
Atherden, S. M., Barnes, N. D., & Grant, D. B. (1972) · Archives of Disease in Childhood · doi:10.1136/adc.47.254.602 · Cited by 38
Rezvani, I., Garibaldi, L. R., Digeorge, A. M., & Artman, H. G. (1983) · Pediatric Research · doi:10.1203/00006450-198302000-00010 · Cited by 33 · cited 1×
“Third, dehydroepiandrosterone sulfate, the predominant adrenal androgen precursor in healthy individuals is suppressed in patients with CAH for reasons that are not quite clear [5, 6].”
BackgroundCavallo, A., Corn, C. R., Bryan, G. T., & Meyer, W. J. (1979) · The Journal of Pediatrics · doi:10.1016/s0022-3476(79)80078-5 · Cited by 29
Ghizzoni, L., Bernasconi, S., Virdis, R., Vottero, A., Ziveri, M., Volta, C., Iughetti, L., & Giovannelli, G. (1994) · Metabolism · doi:10.1016/0026-0495(94)90107-4 · Cited by 20
Juniarto, A. Z., Goossens, K., Setyawati, B. A., Drop, S. L. S., de Jong, F. H., & Faradz, S. M. (2011) · PubMed · Cited by 16
Canonical and Noncanonical Androgen Metabolism and Activity
Storbeck, K., & Mostaghel, E. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_11 · Cited by 11 · cited 1×
“The reason for this is not quite clear; however, 11OHT appears to be directly produced by the adrenal cortex, whereas 11KT is produced in the periphery from excess adrenal metabolites, predominantly from 11OHA4, via 11KA4 [28, 29].”
BackgroundKeenan, B. S., McNeel, R. L., BARRETT, G. N., Holcombe, J. H., Kirkland, R. T., & Clayton, G. W. (1979) · PubMed · Cited by 9
[Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia].
Xiao, H., Ma, H., Su, Z., Du, M., Li, Y., Chen, H., & Chen, Q. (2012) · PubMed · Cited by 1
Research works printed but not linked: 2
- Soldin, Androstenedione.
- Keenan, 1979, Androstenedione concentration as an index of adrenal androgen suppression, J Lab Clin Med., 94, 799
Cited by
Basics of androgen synthesis and action
Naamneh Elzenaty, R., du Toit, T., & Flück, C. E. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101665 · Cited by 199
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationDisorders of Sex Development of Adrenal Origin
Finkielstain, G. P., Vieites, A., Bergadá, I., & Rey, R. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770782 · Cited by 67
“On the other hand, 11-ketoandrostenedione and 11-ketotestosterone are produced in the kidneys from 11-hydroxyandrostenedione by 11b-hydroxysteroid dehydrogenase type 2 (63).”
BackgroundThe clinical and biochemical significance of 11-oxygenated androgens in human health and disease
Storbeck, K.-H., & O’Reilly, M. W. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad047 · Cited by 63
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Self-citation
Metadata
- Authors
- Jha, S., Turcu, A. F., Sinaii, N., Brookner, B., Auchus, R. J., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- University of Michigan (US)
- Corresponding author
- Merke, Deborah P
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2020-12-11
- Volume
- 5
- Issue
- 2
- Pages
- bvaa192-bvaa192
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC7796775
- OpenAlex
- W3123696312
- Cited by
- 39
- References
- 40
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 8 · 2023: 8 · 2022: 4 · 2021: 10
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- Locations
- Journal of the Endocrine Society (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (1K08DK109116)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, 11-ketotestosterone, 17-hydroxyprogesterone, androstenedione, disease control assessment, precocious puberty
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.